Search results for Citius Oncology

Citius Oncology, Inc. Secures Up to $36.5 Million in Debt and Equity Capital to Accelerate LYMPHIR® Commercialization

Avenue Capital Group to provide up to $25 Million via Senior Credit Facility with an initial $10 million tranche funded at closing; additional tranches subject to certain condition...

Citius Oncology sees first international shipment of LYMPHIR to Europe

Cranford-based Citius Oncology, Inc., an oncology‑focused biopharmaceutical company and majority‑owned subsidiary of Citius Pharmaceuticals, Inc., announced the first shipment of L...

Oncology

Oncology Anonymous (not verified) Tue, 05/19/2026 - 08:34 field_thread_url https://cafepharma.com/boards/threads/oncology.709375/ board...

Triomics Secures $22M to Automate Oncology AI Chart Abstraction

What You Should Know Oncology AI innovator Triomics has announced a $22M Series B financing round led by Battery Ventures, pushing its total venture funding past $36 million. The e...

Oricell Lands $110M to Take Cell Therapy to New Territory in Cancer

There are no FDA-approved therapies for GPC3, a protein highly expressed by liver cancers. Oricell Therapeutics claims its cell therapy could be best in this class, but it faces co...

Triomics nabs $22M to bring oncology-specific AI to cancer centers

The Series B round was led by Battery Ventures.

AbbVie Oncology

AbbVie Oncology Anonymous (not verified) Tue, 04/07/2026 - 20:01 field_thread_url https://cafepharma.com/boards/threads/abbvie-oncology.699564/...

<![CDATA[Bridging the Precision Gap: Accelerating Clinical Adoption of Companion Diagnostics in Oncology]]>

RBC Capital Lifts PT on CG Oncology (CGON), Calls PIVOT-006 a Complex Catalyst

CareDx to Acquire Naveris for $160M to Expand into HPV-Driven Cancer MRD Monitoring

What You Should Know CareDx has entered into a definitive agreement to acquire Naveris, a precision oncology company specializing in blood-based monitoring for viral-mediated cance...

Obsidian, Galera Merger Comes With $350M Infusion for Cancer Drug Trials

Obsidian Therapeutics aims to show its TIL cell therapy has advantages over an Iovance Biotherapeutics TIL therapy marketed for treating melanoma. Obsidian’s merger with Galera The...

Oricell closes a ‘pre-IPO’ megaround to aim CAR-T at solid tumors

The Shanghai-based biotech has a cell therapy that, if successful in testing, could become the first treatment of its kind for liver cancer. 

Cell therapy biotech Obsidian leverages Galera reverse merger to go public

After initiating a wind-down more than 18 months ago and exploring liquidation, Galera Therapeutics has found a partner via a reverse merger with Obsidian Therapeutics that will ta...

Celcuity strengthens case for ASCO-spotlighted breast cancer drug

The new data could support a broader approval submission for a therapy that is already under review and set to be showcased at the year’s biggest meeting for cancer research.

Scaling theranostics through access, safety and trust

Curium’s Mike Patterson on improving access, safety and trust to scale theranostics and enhance patient care.

<![CDATA[Beyond the Molecule: The New Competitive Battlefield in Oncology]]>

CareDx expands into cancer testing with $260M Naveris buy

Transplant-focused precision medicine company CareDx is making a move into the oncology space, scooping up Massachusetts-based biotech Naveris in a deal worth up to $260 million.

Precision Delivered: How Radiopharmaceuticals Are Reshaping Cancer Care

As radiopharmaceuticals continue to evolve, the convergence of scientific innovation, operational practicality, and clinical expertise is opening new possibilities in oncology. Th...

AACR: Former Genentech leader engineers startup with vision for ‘smart’ cancer drugs

Just a few years ago, Daniel Chen, M.D., Ph.D., was spending his days in his backyard, sketching out designs for new antibody-drug conjugates with a friend. Now, he’s sharing with...

Olympus pushes deeper into oncology with $270M BioProtect deal

Olympus is pushing deeper into prostate cancer care with the acquisition of BioProtect, an Israeli company whose biodegradable balloon spacer has been used in more than 11,000 proc...

BioNTech, SynOx plot paths to FDA as trials hit goals in competitive tumor types

The fight for two tumor types is poised to intensify, with BioNTech lining up a challenge to AstraZeneca and SynOx Therapeutics planning to enter a market served by companies inclu...

<![CDATA[John Oyler: Rewiring Operations in Oncology]]>

AACR 2026: Revolution’s next prospect, Merck’s reveal and a lung cancer battle

Featured at this year’s meeting on early cancer research were results from an immunotherapy Merck acquired in 2024 and several targeted medicines for lung tumors.

Two New Takes on Making a Type of Targeted Cancer Therapy Even Better

Sidewinder Therapeutics and Stipple Bio each raised mega-rounds of financing to support their approaches to improving the targeting abilities of antibody drug conjugates for cancer...